ADMA Biologics, Inc. is a biopharmaceutical company dedicated to the development, manufacturing, and commercialization of specialty plasma-derived biologics.
The company focuses on producing immune globulin products that are used to treat immune deficiencies and infectious diseases. ADMA Biologics’ key products include BIVIGAM, an immune globulin intravenous (IVIG) product, and ASCENIV, an IVIG product specifically designed to treat primary immune deficiency disease (PIDD).
The company’s growth is driven by the increasing prevalence of immune deficiencies and the rising demand for plasma-derived therapies. Additionally, advancements in biotechnology and a strong pipeline of innovative products contribute to their growth. ADMA Biologics’ commitment to high-quality manufacturing processes and regulatory compliance ensures the safety and efficacy of their products.
As the healthcare industry continues to advance and the need for effective immune therapies grows, ADMA Biologics is well-positioned to capitalize on these trends, providing essential treatments that improve patient outcomes and quality of life.
